UBS Group
DMAC icon

UBS Group’s DiaMedica Therapeutics DMAC Stock Holding History

UBS Group’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$58.6K Buy
8,661
+5,055
+140% +$40.1K ﹤0.01% 7274
2025
Q4 		$28.7K Sell
3,606
-9,734
-73% -$72.8K ﹤0.01% 7552
2025
Q3 		$91.6K Buy
13,340
+5,074
+61% +$27.5K ﹤0.01% 7181
2025
Q2 		$32.2K Buy
8,266
+3,884
+89% +$15.1K ﹤0.01% 8108
2025
Q1 		$16.6K Buy
4,382
+2,613
+148% +$14.9K ﹤0.01% 8349
2024
Q4 		$9.61K Sell
1,769
-10,970
-86% -$51.7K ﹤0.01% 8350
2024
Q3 		$53.4K Buy
+12,739
New +$47K ﹤0.01% 6777
2024
Q2 		– Sell
-1,926
Closed -$5.33K – 9628
2024
Q1 		$5.33K Buy
+1,926
New +$5.59K ﹤0.01% 7547
2023
Q4 		– Sell
-84
Closed -$217 – 9408
2023
Q3 		$217 Buy
+84
New +$270 ﹤0.01% 8685
2023
Q2 		– Sell
-2,038
Closed -$3.12K – 9048
2023
Q1 		$3.12K Sell
2,038
-1,719
-46% -$2.73K ﹤0.01% 8378
2022
Q4 		$5.94K Sell
3,757
-3,434
-48% -$4.63K ﹤0.01% 9106
2022
Q3 		$9K Buy
7,191
+4,161
+137% +$6.5K ﹤0.01% 8567
2022
Q2 		$6K Buy
3,030
+2,080
+219% +$4.85K ﹤0.01% 8663
2022
Q1 		$2K Sell
950
-3,668
-79% -$10.4K ﹤0.01% 9618
2021
Q4 		$17K Buy
+4,618
New +$18.1K ﹤0.01% 8054
2021
Q3 		– Sell
-20,715
Closed -$92K – 9634
2021
Q2 		$92K Buy
20,715
+19,665
+1,873% +$161K ﹤0.01% 5951
2021
Q1 		$10K Buy
1,050
+136
+15% +$1.27K ﹤0.01% 7917
2020
Q4 		$9K Buy
+914
New +$5K ﹤0.01% 7555
2020
Q3 		– Sell
-589
Closed -$4K – 8058
2020
Q2 		$4K Sell
589
-7,911
-93% -$35.3K ﹤0.01% 7442
2020
Q1 		$24K Buy
+8,500
New +$35.1K ﹤0.01% 6370
2019
Q4 		– Sell
-2,354
Closed -$5K – 8152
2019
Q3 		$5K Buy
2,354
+104
+5% +$336 ﹤0.01% 7463
2019
Q2 		$11K Buy
+2,250
New +$7.78K ﹤0.01% 7004
2019
Q1 		– Sell
-1,323
Closed -$4K – 7796
2018
Q4 		$4K Buy
+1,323
New +$4.16K ﹤0.01% 7622

Other funds holding DMAC

CLG
Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

UBS Group's DMAC Position: Q1 2026 in Review

UBS Group increased its DiaMedica Therapeutics (DMAC) stake by 140% in Q1 2026, buying an estimated $40.1K and bringing the position to 8,661 shares worth $58.6K. The position accounts for ﹤0.01% of the portfolio, ranked #7274.

UBS Group first reported a position in DMAC in Q4 2018 and has held it in 23 quarters since. The position peaked at $92K in Q2 2021. 98 funds tracked by Wall St. Rank hold DMAC as of Q1 2026.

  • UBS Group held 8,661 shares of DiaMedica Therapeutics worth $58.6K as of Q1 2026.
  • UBS Group bought 5,055 DiaMedica Therapeutics shares in Q1 2026, an estimated $40.1K.
  • DiaMedica Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #7274 holding.
  • UBS Group first reported a position in DiaMedica Therapeutics in Q4 2018 and has held it in 23 quarters since.
  • UBS Group's DiaMedica Therapeutics position peaked at $92K in Q2 2021.
  • 98 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.